LXEO Fair Value — Lexeo Therapeutics, Inc. Common Stock

Biotechnology · Institutional-depth multi-model valuation on Equity Rank

Current Price
$5.28
Consensus Fair Value
$8.09
Margin of Safety
53.2%

When does LXEO report earnings?

Lexeo Therapeutics, Inc. Common Stock (LXEO) is next scheduled to report earnings on Aug 13, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-0.31.

Heading into this report, the model's fair value estimate sits 53.2% below the current price (model fair value differential above current price). Descriptive context only — not a forecast of the earnings result.

Earnings dates and estimates are sourced from third-party data and may change or lag. Informational only.

How LXEO's valuation models agree

Equity Rank computed model fair value for LXEO from 1 independent valuation methods with sufficient data. 1 place fair value above the current price of $5.28, and 0 place it below. The model-blended estimate lands at $8.09 — a model fair value differential of 53.2% above the current price under these model assumptions. The larger group corresponds to potential undervaluation versus the current price.

Models: FV above price
1
Models: FV below price
0
Models compared
1

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

LXEO fundamental profile

Equity Rank's fundamental strength composite scores LXEO at 36.1/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About LXEO

Lexeo Therapeutics, Inc. Common Stock (LXEO) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Stocks in Biotechnology

JNJ · UNH · PFE · ABBV · MRK

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator